Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.7699
-0.0101 (-1.29%)
At close: Feb 11, 2026, 4:00 PM EST
0.7303
-0.0396 (-5.14%)
After-hours: Feb 11, 2026, 6:07 PM EST
Biofrontera Employees
As of December 31, 2024, Biofrontera had 93 total employees, including 92 full-time and 1 part-time employees. The number of employees increased by 8 or 9.41% compared to the previous year.
Employees
93
Change (1Y)
8
Growth (1Y)
9.41%
Revenue / Employee
$399,613
Profits / Employee
-$188,946
Market Cap
8.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 93 | 8 | 9.41% | 92 | 1 |
| Dec 31, 2023 | 85 | 4 | 4.94% | 83 | 2 |
| Dec 31, 2022 | 81 | 12 | 17.39% | 81 | 0 |
| Dec 31, 2021 | 69 | 13 | 23.21% | 69 | 0 |
| Dec 31, 2020 | 56 | - | - | 56 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| China Pharma Holdings | 224 |
| IM Cannabis | 95 |
| Sunshine Biopharma | 52 |
| cbdMD | 42 |
| RedHill Biopharma | 35 |
| InMed Pharmaceuticals | 13 |
| Shuttle Pharmaceuticals Holdings | 9 |
| Gelteq | 8 |
BFRI News
- 11 hours ago - Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma - GlobeNewsWire
- 2 days ago - Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint - GlobeNewsWire
- 4 weeks ago - Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth - GlobeNewsWire
- 4 weeks ago - Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones - GlobeNewsWire
- 7 weeks ago - Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio - GlobeNewsWire
- 2 months ago - Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT - GlobeNewsWire
- 3 months ago - Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript - Seeking Alpha